Medical device cytotoxicity testing is a fundamental in vitro biological safety evaluation that verifies whether a device or its materials release substances toxic to living cells. Conducted in accordance with ISO 10993-5 and GB/T 16886.5, it is typically the first biocompatibility screen required for any medical device that directly or indirectly contacts patient tissue. This guide explains the testing principles, sample requirements, methods, acceptance criteria, and practical applications of cytotoxicity testing for medical devices.
Technical Overview
Cytotoxicity refers to the ability of a substance to cause adverse effects on cultured cells, including cell lysis, inhibition of growth, reduced metabolic activity, and morphological degeneration. For medical devices, cytotoxicity testing evaluates whether toxic leachable substances—such as residual monomers, additives, plasticizers, degradation products, sterilant residues, or processing contaminants—migrate from the device or its materials into the cellular environment.
The internationally recognized standard for this evaluation is ISO 10993-5 (Biological Evaluation of Medical Devices—Part 5: Tests for In Vitro Cytotoxicity), which is technically aligned with the Chinese national standard GB/T 16886.5. Related method standards include ASTM F813 and ASTM F895 for direct and indirect contact procedures. Under the risk management framework of ISO 10993-1, cytotoxicity testing, together with sensitization and irritation testing, forms the core baseline battery of biological evaluation for virtually all devices that contact body tissues or body fluids.
In vitro cytotoxicity testing is widely used in the medical device industry because it is rapid, sensitive, reproducible, and does not require animal subjects. It provides an early indication of biological incompatibility and helps manufacturers screen materials during design, validate finished devices before regulatory submission, and support change control throughout the product lifecycle.
Testing Samples
Cytotoxicity testing applies to finished devices, device components, and raw materials across all patient-contact categories defined in ISO 10993-1. Typical sample categories include:
Surface-Contacting Devices
Devices contacting intact skin or mucosal membranes, such as adhesive dressings, bandages, electrodes, examination gloves, prosthetic limbs, dental prostheses, and topical compression devices.
Externally Communicating Devices
Devices that enter the body through natural or surgical openings or interface with the blood path, including infusion sets, syringes, hypodermic needles, catheters, blood administration sets, extracorporeal circuits, dialyzers, and endoscopes.
Implantable Devices
Devices placed surgically or otherwise into the body for short-term or long-term residence, such as orthopedic plates and screws, bone substitutes, vascular stents, pacemaker leads, intraocular lenses, dental implants, and absorbable sutures.
Materials and Components
Polymeric resins, elastomers, metals and alloys, ceramics, coatings, adhesives, printing inks, and primary packaging materials intended for device contact. Testing materials at the design stage enables early screening before tooling and production commitments.
Testing Items
Core testing items for cytotoxicity evaluation include the following:
- In vitro cytotoxicity test (extract/elution method) — the most widely applied procedure for most device types
- In vitro cytotoxicity test (direct contact method) — for flat films, sheets, and low-density materials
- In vitro cytotoxicity test (indirect contact/agar diffusion method) — for high-density solid materials and molded components
- Quantitative cell viability assays, including MTT reduction, CCK-8/WST-8, and neutral red uptake
- Qualitative morphological evaluation of cell lysis, rounding, detachment, and membrane integrity under light microscopy
- Optional colony forming efficiency assay for the assessment of long-term proliferative capacity
Testing Methods
Sample Preparation and Extraction
Sample extraction is performed in accordance with ISO 10993-12. The preferred extraction vehicle is complete culture medium (such as MEM supplemented with serum), which supports both extraction and cell viability; other vehicles include physiological saline and purified water where justified. Standard extraction conditions include 37°C for 24 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour, with the 37°C/24-hour condition being the most common for finished devices. Extraction ratios are based on sample thickness and geometry—for example, 6 cm²/mL for thin films below 0.5 mm, 3 cm²/mL for materials of 0.5 mm to 1 mm, and mass-based ratios of 0.1 g/mL to 0.2 g/mL for irregular or thick solids. Samples should represent the final product in its sterilized, ready-to-use condition.
Extract (Elution) Test
The test extract is applied to monolayer cultures of mammalian cells, most commonly L929 mouse fibroblasts, and incubated at 37°C in a 5% carbon dioxide atmosphere for 24 to 72 hours. Cell response is assessed both quantitatively, using a colorimetric viability assay, and qualitatively, by microscopic examination of cellular morphology.
Direct Contact Test
A sterile sample is placed directly onto the cell monolayer, and any local cytotoxic effect caused by direct physical or chemical interaction is observed after incubation. This method is suitable for materials where surface contact is clinically relevant and leaching is limited.
Indirect Contact (Agar Diffusion) Test
A thin agar or agarose layer is placed over the cell monolayer to protect the cells, and the sample is positioned on the agar surface. Diffusible toxic substances migrate through the agar and produce a measurable zone of cell lysis or decolorization, allowing semi-quantitative grading of toxicity.
Quantitative Viability Assays
The MTT assay is the reference quantitative technique: viable cells reduce the yellow tetrazolium salt to purple formazan crystals, and absorbance measured near 570 nm is proportional to metabolic activity. Cell viability is calculated as the ratio of sample well absorbance to blank control absorbance. WST-8/CCK-8 and neutral red uptake assays provide validated alternatives for different laboratories and sample types.
Controls and Acceptance Criteria
Each test run includes validated negative controls (such as high-density polyethylene and the blank extraction vehicle) and positive controls (such as sodium dodecyl sulfate solution or latex extract) to confirm system sensitivity. Acceptance is based on two complementary criteria:
- Quantitative criterion: cell viability of the test sample must be at least 70% of the blank control; a reduction greater than 30% indicates potential cytotoxicity
- Qualitative criterion: microscopic reactivity is graded on a 0 to 4 scale (none, slight, mild, moderate, severe); grades 0 and 1 are generally considered acceptable
Applications
Cytotoxicity testing supports medical device manufacturers at every stage of the product lifecycle:
- Regulatory registration dossiers submitted to national medical device authorities for market approval
- Design-stage screening and comparison of candidate materials, additives, and processing methods
- Verification of the baseline biocompatibility battery for new device families and product lines
- Change control assessment following material substitution, supplier change, manufacturing process modification, or sterilization method changes
- Shelf-life and aging studies confirming that storage does not generate toxic degradation products
- Supporting documentation for CE technical files and other international market access submissions
FAQ
Which standards govern medical device cytotoxicity testing?
ISO 10993-5 is the primary international standard, and GB/T 16886.5 is the corresponding Chinese national standard with essentially aligned technical requirements. Method-level guidance for extraction is provided by ISO 10993-12, with ASTM F813 and ASTM F895 covering direct and indirect contact procedures.
Which cell line is used?
The L929 mouse fibroblast cell line is the most widely used because of its documented sensitivity and reproducibility. Other validated lines, such as BALB/3T3 fibroblasts, may be used provided the laboratory demonstrates equivalent sensitivity with qualified controls.
How long does the test take?
A standard extract test, including sample extraction, cell culture, exposure, and quantitative evaluation, typically requires two to four weeks. Complex devices requiring special extraction or repeated confirmation may require additional time.
What is the pass criterion?
For the quantitative MTT-based evaluation, the sample meets the requirement when mean cell viability is at least 70% of the blank control. Under the qualitative scheme, a reactivity grade of 0 or 1 is considered non-cytotoxic.
Should the test be performed on materials or finished devices?
Material-level testing is acceptable for early screening and design selection, but biological evaluation for regulatory submission should be performed on the finished device in its final manufactured, sterilized, and packaged condition, since processing, sterilization, and packaging can all introduce extractable substances.
Why are positive and negative controls required in every test?
Controls verify that the cell culture system is viable and responsive throughout the exposure period. The negative control confirms the absence of background toxicity, while the positive control demonstrates that the cells can detect a known cytotoxic agent, ensuring the validity of negative results.
How does sterilization affect the test outcome?
Sterilization can alter material chemistry or leave residues, such as ethylene oxide by-products, that influence cytotoxicity. Testing should therefore be performed on sterilized final products, and any sterilization residues should be verified as within acceptable limits prior to biological evaluation.